Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3255)
All Articles published online
|
Feb 15, 2003 (publication date) through Jun 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, Wang HY, Wu MC. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 2003; 9(2): 359-363 [PMID: 12532467 DOI: 10.3748/wjg.v9.i2.359] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v9/i2/359.htm |
| Number | Citing Articles |
| 1 |
Daria Golosova, Vladislav Levchenko, Olha Kravtsova, Oleg Palygin, Alexander Staruschenko. Acute and long-term effects of cannabinoids on hypertension and kidney injury. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-09902-6
|
| 2 |
Mirjam Kuipers, Ronald Smulders, Walter Krauwinkel, Timothy Hoon. Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects With Hepatic Impairment. Journal of Pharmacological Sciences 2006; 102(4): 405 doi: 10.1254/jphs.FP0060311
|
| 3 |
Daniela Fanni, Federica Pinna, Clara Gerosa, Pasquale Paribello, Bernardo Carpiniello, Gavino Faa, Mirko Manchia. Anatomical distribution and expression of CYP in humans: Neuropharmacological implications. Drug Development Research 2021; 82(5): 628 doi: 10.1002/ddr.21778
|
| 4 |
Xinhui Chen, Xiaoming Cui, Nathalie Pognan, Michelle Quinlan, Shruti Kapoor, Gholamreza Rahmanzadeh, Monica Giovannini, Thomas C. Marbury. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study. British Journal of Clinical Pharmacology 2022; 88(1): 91 doi: 10.1111/bcp.14929
|
| 5 |
Craig D. Fisher, Andrew J. Lickteig, Lisa M. Augustine, James Ranger-Moore, Jonathan P. Jackson, Stephen S. Ferguson, Nathan J. Cherrington. Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition 2009; 37(10): 2087 doi: 10.1124/dmd.109.027466
|
| 6 |
Jinguang Ruan. Serum Alanine Transaminase Total Bilirubin Concentrations Predict CYP3A Activity as Measured by Midazolam and 1’-Hydroxylation. Medical Science Monitor 2015; 21: 396 doi: 10.12659/MSM.892044
|
| 7 |
Sha Di, Lin Han, Xuedong An, Ran Kong, Zezheng Gao, Yingying Yang, Xinmiao Wang, Pei Zhang, Qiyou Ding, Haoran Wu, Han Wang, Linhua Zhao, Xiaolin Tong. In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications. Journal of Ethnopharmacology 2021; 276: 114180 doi: 10.1016/j.jep.2021.114180
|
| 8 |
Chengliang Zhang, Yanjiao Xu, Ping Gao, Jingli Lu, Xiping Li, Dong Liu. Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rats. International Immunopharmacology 2015; 24(2): 153 doi: 10.1016/j.intimp.2014.12.003
|
| 9 |
Hiroko Furo, Timothy Wiegand, Meenakshi Rani, Diane G Schwartz, Ross W Sullivan, Peter L Elkin. Association Between Buprenorphine Dose and the Urine “Norbuprenorphine” to “Creatinine” Ratio: Revised. Substance Abuse: Research and Treatment 2023; 17: 117822182311537 doi: 10.1177/11782218231153748
|
| 10 |
Mario M. Alba, Brandon Ebright, Brittney Hua, Ielyzaveta Slarve, Yiren Zhou, Yunyi Jia, Stan G. Louie, Bangyan L. Stiles. Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development. Frontiers in Physiology 2023; 14 doi: 10.3389/fphys.2023.1098467
|
| 11 |
Alexander Elkader, Beth Sproule. Buprenorphine. Clinical Pharmacokinetics 2005; 44(7): 661 doi: 10.2165/00003088-200544070-00001
|
| 12 |
Nattharat Jearapong, Waranya Chatuphonprasert, Kanokwan Jarukamjorn. Effect of tetrahydrocurcumin on the profiles of drug-metabolizing enzymes induced by a high fat and high fructose diet in mice. Chemico-Biological Interactions 2015; 239: 67 doi: 10.1016/j.cbi.2015.06.022
|
| 13 |
Sherif M. Shoieb, Mahmoud A. El-Ghiaty, Mohammed A. Alqahtani, Ayman O.S. El-Kadi. Cytochrome P450-derived eicosanoids and inflammation in liver diseases. Prostaglandins & Other Lipid Mediators 2020; 147: 106400 doi: 10.1016/j.prostaglandins.2019.106400
|
| 14 |
Rashmi R. Shah. Drug development and use in the elderly: search for the right dose and dosing regimen. British Journal of Clinical Pharmacology 2004; 58(5): 452 doi: 10.1111/j.1365-2125.2004.02228.x
|
| 15 |
L.‐Q. YANG, J.‐C. SONG, M. G. IRWIN, J.‐G. SONG, Y.‐M. SUN, W.‐F. YU. A clinical prospective comparison of anesthetics sensitivity and hemodynamic effect among patients with or without obstructive jaundice. Acta Anaesthesiologica Scandinavica 2010; 54(7): 871 doi: 10.1111/j.1399-6576.2010.02222.x
|
| 16 |
|
| 17 |
Peter N. Morcos, Yumi Cleary, Carolina Sturm‐Pellanda, Elena Guerini, Markus Abt, Massimiliano Donzelli, Faye Vazvaei, Bogdana Balas, Neil Parrott, Li Yu. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib. The Journal of Clinical Pharmacology 2018; 58(12): 1618 doi: 10.1002/jcph.1286
|
| 18 |
Michael Soyka, Markus Backmund, Peggy Schmidt, Sabine Apelt. Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: Results from a 12-month observational study. The American Journal on Addictions 2014; 23(6): 563 doi: 10.1111/j.1521-0391.2014.12131.x
|
| 19 |
CY Ahn, SK Bae, SH Bae, T Kim, YS Jung, YC Kim, MG Lee, WG Shin. Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. British Journal of Pharmacology 2009; 156(6): 1019 doi: 10.1111/j.1476-5381.2008.00105.x
|
| 20 |
Shih-Wei Lee, Pei-Tzu Chen, Chi-Wei Liu, Yuan-Hsu Li, Lawrence Shih-Hsin Wu.
Polymorphism of
CYP3A4*18
is associated with anti-tuberculosis drug-induced hepatotoxicity
. Pharmacogenomics 2024; : 1 doi: 10.1080/14622416.2024.2346069
|
| 21 |
Mark K. Greenwald, Sandra D. Comer, David A. Fiellin. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy. Drug and Alcohol Dependence 2014; 144: 1 doi: 10.1016/j.drugalcdep.2014.07.035
|
| 22 |
Arwa R. Althaher, Yazun Jarrar, Mahmood Ayad Al-Ibadah, Ruba Balasmeh, Qais Jarrar, Dina Abulebdah. Effects of Calamintha incana (Sm.) Helder Ethanolic Extract on the mRNA
Expression of Drug-metabolizing cyp450s in the Mouse Livers. MicroRNA 2024; 13(1): 63 doi: 10.2174/0122115366268781231205103752
|
| 23 |
Gail D. Anderson, Shahin Hakimian. Pharmacokinetic of Antiepileptic Drugs in Patients with Hepatic or Renal Impairment. Clinical Pharmacokinetics 2014; 53(1): 29 doi: 10.1007/s40262-013-0107-0
|
| 24 |
Yan Pan, Premika Jagadish, Ung Yee Tze, Sharoen Lim Yu Ming, Lim Kuan Hon, Jason Loo Siau Ee, Yuh Fen Pung, Lamia Noushin Sadeque Chowdhury, Shang Tao. Modulatory Effects of Mangiferin Isolated from Aquilaria Plants on
Human Cytochrome P450 Enzyme (CYP) Activities In vitro and In silico
Studies. The Natural Products Journal 2023; 13(8) doi: 10.2174/2210315513666230307115348
|
| 25 |
Rashmi R Shah. Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules. Expert Opinion on Drug Safety 2005; 4(1): 103 doi: 10.1517/14740338.4.1.103
|
| 26 |
Yun Wang, Xinrui Xing, Yan Cao, Liang Zhao, Sen Sun, Yang Chen, Yifeng Chai, Si Chen, Zhenyu Zhu. Development and Application of an UHPLC-MS/MS Method for Comparative Pharmacokinetic Study of Eight Major Bioactive Components from Yin Chen Hao Tang in Normal and Acute Liver Injured Rats. Evidence-Based Complementary and Alternative Medicine 2018; 2018: 1 doi: 10.1155/2018/3239785
|
| 27 |
Devaraj Venkatapura Chandrashekar, Barent N. DuBois, Mamunur Rashid, Reza Mehvar. Effects of chronic cirrhosis induced by intraperitoneal thioacetamide injection on the protein content and Michaelis–Menten kinetics of cytochrome P450 enzymes in the rat liver microsomes. Basic & Clinical Pharmacology & Toxicology 2023; 132(2): 197 doi: 10.1111/bcpt.13813
|
| 28 |
Miroslav Dostalek, Michael H. Court, Bingfang Yan, Fatemeh Akhlaghi. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. British Journal of Pharmacology 2011; 163(5): 937 doi: 10.1111/j.1476-5381.2011.01270.x
|
| 29 |
Eman El‐Khateeb, Adam S. Darwich, Brahim Achour, Varinder Athwal, Amin Rostami‐Hodjegan. Review article: time to revisit Child‐Pugh score as the basis for predicting drug clearance in hepatic impairment. Alimentary Pharmacology & Therapeutics 2021; 54(4): 388 doi: 10.1111/apt.16489
|
| 30 |
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, Stéphane Delahaye, Urs Duthaler, Clemens Muehlan, Stephan Krähenbühl. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clinical Pharmacokinetics 2021; 60(10): 1349 doi: 10.1007/s40262-021-01028-8
|
| 31 |
Diane Ramsden, Conrad Fung, Niresh Hariparsad, Jane R. Kenny, Michael Mohutsky, Neil J. Parrott, Sarah Robertson, Donald J. Tweedie. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates. Drug Metabolism and Disposition 2019; 47(10): 1206 doi: 10.1124/dmd.119.087270
|
| 32 |
Michael J. Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C. Marbury, Karthik Venkatakrishnan, Neeraj Gupta. Brigatinib pharmacokinetics in patients with chronic hepatic impairment. Investigational New Drugs 2023; 41(3): 402 doi: 10.1007/s10637-023-01339-6
|
| 33 |
Trine Naalsund Andreassen, Pål Klepstad, Andrew Davies, Kristin Bjordal, Staffan Lundström, Stein Kaasa, Ola Dale. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. European Journal of Clinical Pharmacology 2011; 67(5): 493 doi: 10.1007/s00228-010-0948-5
|
| 34 |
Shashank Bhattarai, Sandip R. Pradhan, Shraddha Bhattarai. Low-dose atorvastatin therapy induced rhabdomyolysis in a liver cirrhosis patient – a case report. Annals of Medicine & Surgery 2023; 85(10): 5232 doi: 10.1097/MS9.0000000000001231
|
| 35 |
Raj Vuppalanchi, Tiebing Liang, Chirayu Pankaj Goswami, Rohit Nalamasu, Lang Li, David Jones, Rongrong Wei, Wanqing Liu, Vishal Sarasani, Sarath Chandra Janga, Naga Chalasani, Ranjit Ray. Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis. PLoS ONE 2013; 8(9): e74471 doi: 10.1371/journal.pone.0074471
|
| 36 |
Yoichi Sasaki, Ryotaro Sakamori, Ryoko Yamada, Minoru Shigekawa, Yuki Tahata, Yuki Makino, Tasuku Nakabori, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara. Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation. Hepatology Research 2019; 49(11): 1357 doi: 10.1111/hepr.13379
|
| 37 |
Urs Duthaler, Fabio Bachmann, Claudia Suenderhauf, Tanja Grandinetti, Florian Pfefferkorn, Manuel Haschke, Petr Hruz, Jamal Bouitbir, Stephan Krähenbühl. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. Clinical Pharmacokinetics 2022; 61(7): 1039 doi: 10.1007/s40262-022-01119-0
|
| 38 |
Eman El-Khateeb, Areti-Maria Vasilogianni, Sarah Alrubia, Zubida M. Al-Majdoub, Narciso Couto, Martyn Howard, Jill Barber, Amin Rostami-Hodjegan, Brahim Achour. Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice. Pharmacology & Therapeutics 2019; 203: 107397 doi: 10.1016/j.pharmthera.2019.107397
|
| 39 |
Craig D. Fisher, Jonathan P. Jackson, Andrew J. Lickteig, Lisa M. Augustine, Nathan J. Cherrington. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Archives of Toxicology 2008; 82(12): 959 doi: 10.1007/s00204-008-0312-z
|
| 40 |
Sung-Joon Cho, Sang-Bum Kim, Hyun-Jong Cho, Saeho Chong, Suk-Jae Chung, Il-Mo Kang, Jangik Ike Lee, In-Soo Yoon, Dae-Duk Kim. Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. Journal of Agricultural and Food Chemistry 2016; 64(27): 5598 doi: 10.1021/acs.jafc.6b01663
|
| 41 |
Fengling Wang, Xue Zhang, Yanyan Wang, Yunna Chen, Huiyu Lu, Xiangyun Meng, Xi Ye, Weidong Chen. Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy. Drug Metabolism and Disposition 2023; 51(5): 543 doi: 10.1124/dmd.122.001131
|
| 42 |
P. N. Sidharta, A. Treiber, J. Dingemanse. Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan. Clinical Pharmacokinetics 2015; 54(5): 457 doi: 10.1007/s40262-015-0255-5
|
| 43 |
Howard Smith, Patricia Bruckenthal. Implications of Opioid Analgesia for Medically Complicated Patients. Drugs & Aging 2010; 27(5): 417 doi: 10.2165/11536540-000000000-00000
|
| 44 |
Hanan Ogaly, Nadia Eltablawy, Adel El-Behairy, Hatim El-Hindi, Reham Abd-Elsalam. Hepatocyte Growth Factor Mediates the Antifibrogenic Action of Ocimum bacilicum Essential Oil against CCl4-Induced Liver Fibrosis in Rats. Molecules 2015; 20(8): 13518 doi: 10.3390/molecules200813518
|
| 45 |
Camille Lenoir, Victoria Rollason, Jules A. Desmeules, Caroline F. Samer. Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.733935
|
| 46 |
Fabiola Delc??, Lydia Tchambaz, Raymond Schlienger, J??rgen Drewe, Stephan Kr??henb??hl. Dose Adjustment in Patients with Liver Disease. Drug Safety 2005; 28(6): 529 doi: 10.2165/00002018-200528060-00005
|
| 47 |
P. Priou, F. Gagnadoux, C. Dehé, J. Hureaux, C. Person, T. Urban, J.-L. Racineux. Pneumopathie médicamenteuse sous traitement par venlafaxine et propranolol. Revue des Maladies Respiratoires 2008; 25(5): 610 doi: 10.1016/S0761-8425(08)71620-6
|
| 48 |
Fiona V. Büdingen, Daniel Gonzalez, Amelia N. Tucker, Hartmut Derendorf. Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments. Therapeutic Advances in Infectious Disease 2014; 2(1): 17 doi: 10.1177/2049936113519089
|
| 49 |
Xiaomei I. Liu, Ruby Leong, Gilbert J. Burckart, André Dallmann. Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug‐Drug Interactions, Pediatric Patients, and Pregnancy and Lactation. The Journal of Clinical Pharmacology 2024; 64(3): 323 doi: 10.1002/jcph.2379
|
| 50 |
Trevor N. Johnson, Koen Boussery, Karen Rowland-Yeo, Geoffrey T. Tucker, Amin Rostami-Hodjegan. A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance. Clinical Pharmacokinetics 2010; 49(3): 189 doi: 10.2165/11318160-000000000-00000
|
| 51 |
C. Denne, A. E. Vogl-Voswinckel, A. Gruebl, S. Burdach. Adrenal Crisis Caused by Inhaled Fluticasone in an Adolescent with Cystic Fibrosis and Advanced Hepatopathy: A Case Report. Case Reports in Pulmonology 2012; 2012: 1 doi: 10.1155/2012/913574
|
| 52 |
Nathalie K. Zgheib, Juan J.L. Lertora, Robert A. Branch. Atkinson's Principles of Clinical Pharmacology. 2022; : 91 doi: 10.1016/B978-0-12-819869-8.00005-7
|
| 53 |
Yang Ge, Shuzhen Chen, Wei Mu, Qian Ba, Jingquan Li, Peizhan Chen, Xianming Wang, Hui Wang. Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma. Cancer Letters 2019; 454: 14 doi: 10.1016/j.canlet.2019.03.030
|
| 54 |
Cindy J. Bednasz, Charles S. Venuto, Qing Ma, Gene D. Morse. Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct‐Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications. Clinical Pharmacology in Drug Development 2017; 6(2): 135 doi: 10.1002/cpdd.313
|
| 55 |
Hebatollah E. Eitah, Hanan Naeim Attia, Ahmed A.F. Soliman, Amina A. Gamal el Din, Khaled Mahmoud, Rabab H. Sayed, Yousreya A. Maklad, Ayman E. El-Sahar. Vitamin D ameliorates diethylnitrosamine-induced liver preneoplasia: A pivotal role of CYP3A4/CYP2E1 via DPP-4 enzyme inhibition. Toxicology and Applied Pharmacology 2023; 458: 116324 doi: 10.1016/j.taap.2022.116324
|
| 56 |
Rashmi R Shah. Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes. Drug Safety 2004; 27(3): 145 doi: 10.2165/00002018-200427030-00001
|
| 57 |
Ling Ye, Xiaoshan Yang, Enshuang Guo, Weiying Chen, Linlin Lu, Ying Wang, Xiaojuan Peng, Tongmeng Yan, Fuyan Zhou, Zhongqiu Liu, Hua Zhou. Sorafenib Metabolism Is Significantly Altered in the Liver Tumor Tissue of Hepatocellular Carcinoma Patient. PLoS ONE 2014; 9(5): e96664 doi: 10.1371/journal.pone.0096664
|
| 58 |
Tamsin A Knox, Lauren Oleson, Lisa L von Moltke, Rhonda C Kaufman, Christine A Wanke, David J Greenblatt. Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis. JAIDS Journal of Acquired Immune Deficiency Syndromes 2008; 49(4): 358 doi: 10.1097/QAI.0b013e31818c7efe
|
| 59 |
Natasha T. Snider, Vyvyca J. Walker, Paul F. Hollenberg. Oxidation of the Endogenous Cannabinoid Arachidonoyl Ethanolamide by the Cytochrome P450 Monooxygenases: Physiological and Pharmacological Implications. Pharmacological Reviews 2010; 62(1): 136 doi: 10.1124/pr.109.001081
|
| 60 |
Mario Congiu, Maurice L Mashford, John L Slavin, Paul V Desmond. Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. Journal of Gastroenterology and Hepatology 2009; 24(6): 1038 doi: 10.1111/j.1440-1746.2009.05800.x
|
| 61 |
|